Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study

SIMPLE SUMMARY: Treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with endocrine therapies. However, limited dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sollena, Pietro, Vasiliki, Nikolaou, Kotteas, Elias, Stratigos, Alexander J., Fattore, Davide, Orlandi, Armando, Mannino, Maria, Di Pumpo, Marcello, Fida, Monika, Starace, Michela, Apalla, Zoe, Romano, Maria Concetta, Riganti, Julia, Segura, Sonia, Martinez, Azael Freites, Fabbrocini, Gabriella, Sibaud, Vincent, Peris, Ketty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377938/
https://www.ncbi.nlm.nih.gov/pubmed/37509319
http://dx.doi.org/10.3390/cancers15143658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377938/
https://www.ncbi.nlm.nih.gov/pubmed/37509319
http://dx.doi.org/10.3390/cancers15143658

Ejemplares similares